Monopar Therapeutics
MNPR
95 hedge funds and large institutions have $576M invested in Monopar Therapeutics in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 32 increasing their positions, 24 reducing their positions, and 14 closing their positions.
186% more capital inflows, than outflows
Capital inflows: $128M | Capital outflows: $44.8M
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
33% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 24
16% more funds holding
Funds holding: 82 → 95 (+13)
0.44% less ownership
Funds ownership: 93.32% → 92.88% (-0.44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$9.7M |
| 2 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$8.87M |
| 3 |
TCG Crossover Management
Palo Alto,
California
|
+$4.41M |
| 4 |
Longaeva Partners
Chicago,
Illinois
|
+$3.46M |
| 5 |
Driehaus Capital Management
Chicago,
Illinois
|
+$3.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sio Capital Management
New York
|
-$9.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.19M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3.49M |
| 4 |
Walleye Capital
New York
|
-$3.46M |
| 5 |
ADAR1 Capital Management
Austin,
Texas
|
-$2.89M |
MNPR Hedge Fund Activity: Q2 2026 in Review
95 of the 8,360 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q2 2026, worth a combined $576M — up 69% from $342M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new MNPR positions and 14 closed out — a net gain of 15 holders — while 32 added to existing stakes and 24 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $9.7M. The largest seller was Sio Capital Management, exiting entirely with an estimated $9.5M sold.
- 95 institutional investors held Monopar Therapeutics (MNPR) as of Q2 2026, up from 82 in Q1 2026.
- Funds reported $576M of Monopar Therapeutics stock for Q2 2026, up 69% quarter-over-quarter.
- 29 funds opened new Monopar Therapeutics positions in Q2 2026 and 14 closed out, a net change of +15 holders.
- The largest Monopar Therapeutics buyer in Q2 2026 was OrbiMed, an estimated $9.7M added.
- The largest Monopar Therapeutics seller in Q2 2026 was Sio Capital Management, an estimated $9.5M sold.
Based on aggregated 13F filings for Q2 2026.